The development of subsensitivity to nebulized atropine sulfate.
Ten adult asthmatic subjects were tested for response to inhaled atropine sulfate before and after 3 weeks of inhaled atropine therapy. Four of the ten initial responders no longer responded after the 3 weeks. The mean FEV1 increase was 0.49 L before treatment and 0.30 L after treatment (P = .025). Subsensitivity to the effects of atropine develops, but may be limited to a subset of patients.
D000328:Adult; D001249:Asthma / Q000188:drug therapy / Q000276:immunology; D001285:Atropine / Q000008:administration & dosage* / Q000276:immunology; D003888:Desensitization, Immunologic; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers
D001285:Atropine